Arrigo, Alessandro
Aragona, Emanuela
Perra, Cristian
Bianco, Lorenzo
Antropoli, Alessio
Saladino, Andrea
Berni, Alessandro
Basile, Giulia
Pina, Adelaide
Bandello, Francesco
Battaglia Parodi, Maurizio
Article History
Received: 30 June 2022
Accepted: 11 January 2023
First Online: 16 January 2023
Competing interests
: Francesco Bandello: Francesco Bandello consultant for Alcon (Fort Worth, Texas, USA), Alimera Sciences (Alpharetta, Georgia, USA), Allergan Inc (Irvine, California, USA), Farmila-Thea (Clermont-Ferrand, France), Bausch And Lomb (Rochester, New York, USA), Genentech (San Francisco, California, USA), Hoffmann-La-Roche (Basel, Switzerland), Novagali Pharma (Évry, France), Novartis (Basel, Switzerland), Bayer Shering-Pharma (Berlin, Germany), Sanofi-Aventis (Paris, France), Thrombogenics (Heverlee, Belgium), Zeiss (Dublin, USA), Pfizer (New York, USA), Santen (Osaka, Japan), Sifi (Aci Sant’Antonio, Italy). All the other authors have no financial disclosures. The authors declare no competing interests.